Characteristics of unpublished registered studies: inactivated virus vaccine (61 studies)
Registration number	Registration date	Status	Design	Interventions	Estimated sample size	Phase
ChiCTR2000034780	8 July 2020	Completed	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	15,000	Phase 3
ChiCTR2100041704	1 January 2021	Completed	Parallel	SARS‐CoV‐2 vaccine	360	Not reported
NCT04691908	31 December 2020	Completed	Parallel	QazCovid‐in	3000	Phase 3
NCT04790851	10 March 2021	Completed	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell) + IIV4 + Inactivated SARS‐CoV‐2 vaccine (vero cell) + pneumococcal vaccine	1152	Phase 4
ChiCTR2100046174	8 May 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	1152	Phase 4
ChiCTR2000040146	22 November 2020	Not recruiting	Parallel	INO‐4800 + CoronaVac	640	Phase 2
ChiCTR2100046227	11 May 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	1404	Phase 4
JPRN‐jRCT2071200106	3 March 2021	Not recruiting	Parallel	KD‐414	210	Phase 1/Phase 2
NCT04560881	23 September 2020	Not recruiting	Parallel	BBIBP‐CorV	3000	Phase 3
NCT04612972	3 November 2020	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	12,000	Phase 3
NCT04747821	10 February 2021	Not recruiting	Parallel	CoronaVac	27,711	Phase 4
NCT04852705	21 April 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	28,000	Phase 3
NCT04884685	13 May 2021	Not recruiting	Parallel	CoronaVac	500	Phase 2
NCT04894227	20 May 2021	Not recruiting	Parallel	CoronaVac	1080	Phase 4
NCT04917523	8 June 2021	Not recruiting	Parallel	BBIBP‐CorV	1800	Phase 3
NCT04953325	7 July 2021	Not recruiting	Parallel	CoronaVac	270	Phase 4
NCT04956224	9 July 2021	Not recruiting	Parallel	VLA2001	750	Phase 3
PER‐051‐20	18 August 2020	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	12,000	Phase 3
NCT04984408	30 July 2021	Not recruiting	Parallel	BBIBP‐CorV	8825	Phase 3
NCT04992182	5 August 2021	Not recruiting	Parallel	CoronaVac	534	Phase 2
NCT05003466	12 August 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	480	Phase 2
NCT05003479	12 August 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	84	Phase 1
IRCT20210206050259N3	29 August 2021	Not recruiting	Parallel	Inactivated SARS‐CoV‐2 vaccine FAKHRAVAC (MIVAC)	41,128	Phase 3
NCT05035238	3 September 2021	Not recruiting	Parallel	Turkovac	200	Phase 2
CTRI/2021/08/035648	13 August 2021	Not recruiting	Parallel	Covaxin	1100	Phase 4
NCT05046548	16 September 2021	Not recruiting	Parallel	Kovivac	400	Phase 1/Phase 2
NCT05079217	15 October 2021	Not recruiting	Parallel	CoronaVac	1200	Phase 4
NCT04993365	6 August 2021	Not recruiting	Parallel	CoronaVac + influenza vaccine + pneumococcal vaccine	440	Phase 4
NCT05079152	15 October 2021	Not recruiting	Parallel	BBIBP‐CorV + influenza vaccine + pneumococcal vaccine	1404	Phase 4
IRCT20201202049567N1	15 December 2020	Ongoing	Parallel	SARS‐CoV‐2 vaccine	56	Phase 1
IRCT20201202049567N2	13 March 2021	Ongoing	Parallel	Antigen protein	32	Phase 1
IRCT20201202049567N3	13 March 2021	Ongoing	Parallel	Antigen protein	20,000	Phase 2/Phase 3
IRCT20210206050259N1	8 March 2021	Ongoing	Factorial	Inactivated SARS‐CoV‐2 vaccine FAKHRAVAC (MIVAC)	135	Phase 1
IRCT20210206050259N2	8 June 2021	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine FAKHRAVAC (MIVAC)	500	Phase 2
ChiCTR2000039000	13 October 2020	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	600	Phase 3
ChiCTR2100043907	5 March 2021	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	16	Phase 4
ChiCTR2100045109	7 April 2021	Ongoing	Parallel	Inactivated COVID‐19 vaccine	472	Not reported
ChiCTR2100047917	27 June 2021	Ongoing	Sequential assignment	Inactivated SARS‐CoV‐2 vaccine (vero cell)	20	Phase 1
CTRI/2020/07/026300	26 August 2020	Ongoing	Parallel	Covaxin	1125	Phase 1/Phase 2
CTRI/2020/09/027674	8 September 2020	Ongoing	Adaptive	Covaxin	124	Phase 1/Phase 2
NCT04470609	14 July 2020	Ongoing	Parallel	SARS‐CoV‐2 vaccine	471	Phase 1/Phase 2
NCT04617483	5 November 2020	Ongoing	Parallel	SARS‐CoV‐2 vaccine (inactivated)	1040	Phase 3
NCT04659239	9 December 2020	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	34,020	Phase 3
NCT04691947	31 December 2020	Ongoing	Parallel	ERUCOV‐VAC	44	Phase 1
NCT04824391	1 April 2021	Ongoing	Parallel	ERUCOV‐VAC	250	Phase 2
NCT04838080	8 April 2021	Ongoing	Parallel	Inactivated COVID‐19 vaccine	38	Phase 1
NCT04863638	28 April 2021	Ongoing	Parallel	BBIBP‐CorV	4400	Phase 4
NCT04864561	29 April 2021	Ongoing	Parallel	VLA2001	4000	Phase 3
NCT04866069	29 April 2021	Ongoing	Parallel	SARS‐CoV‐2 vaccine	50	Phase 1
NCT04942405	28 June 2021	Ongoing	Parallel	CoronaVac	40,800	Phase 3
NCT04962308	14 July 2021	Ongoing	Parallel	CoronaVac	1400	Phase 4
CTRI/2021/04/032942	19 April 2021	Ongoing	Parallel	Covaxin	190	Phase 2
NCT04979949	28 July 2021	Ongoing	Parallel	CoronaVac	111	Phase 2
NCT04992260	5 August 2021	Ongoing	Parallel	CoronaVac	7000	Phase 3
NCT05033847	3 September 2021	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	1800	Phase 3
CTRI/2021/08/035993	27 August 2021	Ongoing	Parallel	Covaxin	608	Phase 2/Phase 3
NCT05043259	14 September 2021	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	420	Phase 1/Phase 2
ChiCTR2100050589	31 August 2021	Ongoing	Sequential assignment	Inactivated SARS‐CoV‐2 vaccine (vero cell)	500	Phase 4
TCTR20210731003	31 July 2021	Ongoing	Parallel	BBIBP‐CorV	960	Phase 2
ChiCTR2100051645	29 September 2021	Ongoing	Parallel	Inactivated SARS‐CoV‐2 vaccine (vero cell)	600	Phase 2
NCT05095298	27 October 2021	Ongoing	Parallel	SARS‐CoV‐2 vaccine (inactivated)	400	Phase 4